Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).

Read more:
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference